Actu-Real’s cross-functional expertise in HEOR assisted a global pharma company in estimating the budget impact of GBM (Glioblastoma)
A global pharma company was seeking a budget impact model to treat recurrent GBM (Glioblastoma)
The client wanted to submit the value dossier in Asia, the UK and 5 key EU markets.
How did we help?
Actu-Real’s pragmatic and fit-for-purpose HEOR solutions helped the client ascertain the incremental budget impact at the annual level between the client’s product, standard of care alone, and standard of care combined with the client’s product. We also evaluated the budget impact of monotherapy and combination therapy in conjunction with standard-of-care treatment.
- We provided population estimates for rGBM from an on-site epidemiological study by the client
- We captured clinical inputs for efficacy and adverse events from published sources supplemented by interviews conducted at 10 area hospitals
- We extracted cost inputs from the medical fees table and product monograph published by the National Ministry of Health